The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R...(l feed and water tochickens exposed to H...),Health
l feed and water to chickens exposed to HPAI (Highly Pathogenic Avian Influenza) H5N1.
Patent For Prophylactic And Anti-Transmissivity Uses Of An Anti-Microbial Composition - This patent provides additional protection to an existing composition patent and further supports on-going investigations and potential commercialization opportunities for compounds against avian flu QR-441(a) and human influenza (QR-435).
Cachexia Treatment Compound - QR-443: Further positive results were obtained for the QR-443 compound for the treatment of Cachexia, a debilitating and life threatening muscle wasting condition associated with cancer, AIDS, renal failure, COPD and rheumatoid arthritis, where inflammation has a significant impact and patients experience loss of weight, muscle atrophy, fatigue, weakness and decreased appetite. A preliminary follow up Cachexia study, evaluating weight loss in mice concluded that QR-443 was as effective in delaying the progression of Cachexia when given orally as it had been shown to be when administered intra-peritoneally in a previous study. The data complements the previous study results demonstrating a correlation between effectiveness and the frequency of administration of the QR-443 compound.
Human clinical safety trial designed to evaluate the effects of QR-449: Based on positive preclinical animal data and Institutional Review Board (IRB) approval human clinical safety trials designed to evaluate the effects of QR- 449 on subjects with Metabolic Syndrome were initiated. People suffering from Metabolic Syndrome are vulnerable to the most dangerous heart attack risk factors; diabetes, abdominal obesity, high cholesterol and high blood pressure.
Presentation at the New York Society of Security Analysts (NYSSA):
Senior management of the Quigley Corporation made a presentation at the
11th Annual Biotech/Specialty Pharma Industry investor conference in New
York City. The presentation is archived for web cast at
'/>"/>
| SOURCE The Quigley Corporation Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
2. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
3. Dialysis Corporation of America Announces Fiscal Year 2007 Earnings Release Date
4. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
5. National Atlantic Holdings Corporation to Report Fourth Quarter and Year-End 2007 Earnings on March 17, 2008
6. Linkwell Corporations Skin Disinfectant Product Chosen for 2008 Beijing Olympic Games
7. Partners Center for Connected Health and EMC Corporation Launch New Web-Based Remote Monitoring Program to Help Employees Fight Hypertension
8. China Bionanometer Industries Corporation Announces New Products for China
9. Centene Corporation Unveils Winners of the 2008 Physician Summit Award
10. Dialysis Corporation of America Announces its Newest Center Opening in South Carolina
11. Harris Corporation Demonstrates Digital Signage(TM) Solutions for Dynamic, Rapid Communications within Healthcare Enterprises
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |